A recent study in Pain Medication News examines the impact of patient punctuality on the management and outcomes of opioid therapy in outpatient pain clinics. It emphasizes the importance of using appointment times effectively for opioid education due to its complexity and how punctuality affects clinic efficiency, patient satisfaction, and medication compliance. With a significant […]
Opiate MME Correlated With Patient Arrival Time Read More »
A recent cross-sectional analysis of IQVIA Longitudinal Prescription Data reveals a concerning increase in dental opioid prescribing during the COVID-19 pandemic. The study, covering the period from 2016 to 2022, initially showed a 45% decrease in dental opioid prescriptions. However, during the pandemic, this positive trend slowed, with a 31.4% surge in dental opioid dispensing
Dental Opioid Prescriptions Increased During COVID-19, Pausing Trends in Reduction Read More »
A recent study published in Addiction examined polysubstance overdose deaths in the United States during the transition to the fourth wave of the drug overdose crisis. The researchers analyzed national death records from 2010 to 2021 and found an over 50 fold increase in overdose deaths involving both fentanyl and stimulants, with the most substantial
New Study: 4th Wave Of Opiate Crisis Skyrockets Read More »
Despite a significant decline in prescription opiate prescribing, opioid deaths are still rising due to synthetic fentanyl. This article discusses the overlooked role of the southern border in this issue.
It’s The Border Stupid… Read More »
Researchers from Boston College, Boston University, and Giner Labs have developed a groundbreaking penny-sized biosensor using atom-thick graphene. This innovative device, described in ACS Nano, is the first to utilize graphene-based field effect transistors for detecting four different opioids simultaneously in wastewater, addressing a key challenge in understanding opioid usage within communities. When an opioid
Is Wastewater Sampling The New Dumpster Diving? Read More »
Join us for a brief informational presentation on the Mate Act – hope this helps answer all your questions!
Mate Act Explained Read More »
The US Drug Enforcement Administration (DEA) has outlined an eight-hour training requirement on the treatment and management of opioid patients. The Medication Access and Training Expansion Act mandates the training for all DEA-registered providers, with the deadline for completion set for the date of a practitioner’s next scheduled DEA registration submission beginning on June 27. Graduates from medical and dental schools are exempt from the requirement. The training does not have to occur in one session, and courses previously undertaken in accordance with state-mandated continuing education will apply.
DEA Issues Guidance on Opioid Treatment Training for Medical Practitioners Read More »
This article discusses the recent approval of the first over-the-counter naloxone nasal spray for use in reversing opioid overdoses. The U.S. Food and Drug Administration (FDA) has approved the first over-the-counter (OTC) naloxone nasal spray, Narcan, to help prevent opioid overdoses. The nasal spray is intended for use in adults and adolescents, and the FDA
FDA Approves OTC Naloxone Read More »
The ADA has issued a FAQ (frequently asked questions) providing additional information regarding the 2022 Omnibus Bill with provisions for the MATE Act – which included a controlled substance education requirement for continuing DEA registration. The FAQ suggests further information and guidance will be forthcoming by the end of March. The Act contains exclusions and
It has come to our attention a little known provision of the federal omnibus bill approved in the waning hours of 2022 included a requirement that could impact your practice if not properly managed. The Medication Access and Training Expansion (MATE) Act, which aims to improve access to medications and expand training for healthcare professionals
Main Menu
User Menu
